The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
 
Antonio D'Alessio
Consulting or Advisory Role - Roche
Speakers' Bureau - AstraZeneca; Chugai/Roche; Eisai; Roche
Travel, Accommodations, Expenses - Roche
 
Pasquale Lombardi
No Relationships to Disclose
 
Bernardo Stefanini
No Relationships to Disclose
 
Julia Blanter
No Relationships to Disclose
 
Fionnuala Crowley
No Relationships to Disclose
 
Daniel Shu
No Relationships to Disclose
 
Vincent Yip
No Relationships to Disclose
 
Sarah Slater
Consulting or Advisory Role - Eisai, Pfizer
 
Madhava Pai
No Relationships to Disclose
 
Robert Goldin
No Relationships to Disclose
 
Stephen Ward
Speakers' Bureau - Astrazeneca, Intercept
Research Funding - Boehringer Ingelheim (Inst)
 
M. Isabel Fiel
No Relationships to Disclose
 
Yung-Yeh Su
No Relationships to Disclose
 
Marina Baretti
Consulting or Advisory Role - Astrazeneca and Eisai
 
Robert Anders
No Relationships to Disclose
 
Mark Yarchoan
Speakers' Bureau - Genentech, Exelixis, AstraZeneca, Replimune, Hepion, Lantheus
Research Funding - NCI/NIH, Fibrolamellar cancer foundation, CRI, Bristol-Myers Squibb, Exelixis, Incyte, and Genentech (Inst)
Other Relationship - cofounder with equity of Adventris Pharmaceuticals
 
Chiun Hsu
Speakers' Bureau - AstraZeneca, Bristol-Myers Squibb/ONO, Roche
Research Funding - National Science and Technology Council (Taiwan) and Bristol-Myers Squibb/ ONO (Inst)
 
Thomas Marron
Consulting or Advisory Role - Abbvie; Arrowhead Pharmaceuticals; Astellas Pharma; AstraZeneca; Avammune; EMD Serono; Geneos; Merck; Regeneron; Replimune; Replimune; Storm Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech
 
Rohini Sharma
No Relationships to Disclose
 
David Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Mursla Bio; Roche/Genentech; Starpharma
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; MiNA Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley
 
NeoHCC Consortium
No Relationships to Disclose